Angiex selected ZingPR to generate excitement and build momentum for the Phase 1 clinical trial of AGX101, a novel antibody-drug conjugate (ADC) designed to revolutionize cancer treatment by targeting tumor blood vessels. The campaign played a crucial role in communicating the potential of AGX101 to transform cancer treatment and attracting support for Angiex's mission.

WideTrial, a startup focused on expanded access programs (EAPs), partnered with ZingPR to announce its role in a major NIH-funded EAP for ALS. The challenge was to generate excitement while establishing credibility and navigating the constraints faced by many startups. How ZingPR helped WideTrial achieve significant media coverage in prominent publications.

Recently, I had the chance to work on a fascinating project: promoting a debate on aging. Not your typical PR gig, right? But that's what I love about this field—the chance to work with innovative companies tackling big challenges. My goal was simple: make this debate unmissable. And more importantly, make it matter. Because the science behind it really matters.

ZingPR helped Transform Materials, a Florida-based deeptech startup, announce a groundbreaking collaboration with Johnson Matthey that's set to revolutionize the PVC industry. Our strategic media outreach focused on highlighting the partnership's environmental benefits, scalability, and industry-leading expertise.

In the world of science PR, it's not enough to have groundbreaking research – you need a story that grips. A narrative that not only informs but also intrigues. So how do you break through the clutter and make your science news sing?

In this episode of "Twinning Strategy," the team discusses tips on attracting press coverage and funding. Learn how to find the right time to start PR, craft compelling stories that journalists (and investors) crave, and even turn crises into positive opportunities.

Launching a new robotics solution is always a challenge. It's highly technical and can be difficult to translate for a general audience. That's why OSARO partnered with ZingPR to craft a compelling media strategy. Instead of focusing on specs, we highlighted the real-world benefits: warehouse safety and efficiency.

rBIO's biosimilar insulin story landed in Wired, MedCity News, and more. See the PR tactics that drove success and get tips for your biotech launch.

With its patented technology that can extend metalens field of view (FOV) to almost 180 degrees without sacrificing imaging quality, 2Pi Optics outperforms conventional wide-FOV refractive optics in size, weight, performance, and cost.

CureLab Oncology’s DNA vaccine Elenagen, in combination with a proven chemotherapy, demonstrates promising clinical results against one of the deadliest forms of ovarian cancer.

It’s incredibly important to have a strong brand image and supporting story before you begin PR. Here are some of our recent branding and website success stories with some hugely promising science startups.

Gero is a cutting-edge biotechnology company dedicated to the mission of curing age-related human diseases and understanding, slowing, and even halting the aging process itself.

By adopting the Optellum Virtual Nodule Clinic, the Interventional Pulmonology team at AtlantiCare's Lung Nodule Clinic, led by Amit Borah, M.D., interventional pulmonologist, can focus on identifying and systematically following up on patients with incidentally detected lung nodules.

Cyclica will apply its AI-enabled drug discovery platform to discover new therapeutic options with the goal of expanding the range of accessible non-hormonal contraceptive choices for women in developing countries.

Two biotech leaders have embarked on a research project to streamline manufacturing of non-viral CRISPR gene editing components. Their goal is to improve the editing efficiency and cell viability of non-viral-based cell therapies.

The clinical benefits currently delivered for terminally ill patients in CureLab’s clinical trial are already exceeding the benefits of new drugs recently approved by the FDA.